Clinical site selection platform RyghtAI has launched a search engine designed to give drug developers and contract research ...
After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...
To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...
Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...
Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage ...
Qiagen is moving into syndromic testing for bloodstream infections with the launch of the Netherlands-based diagnostics maker ...
Clinical trial site network Rare Disease Research (RDR) is partnering with health tech company myTomorrows to increase trial visibility and support more referrals from community and specialist care ...
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts ...
It was as recently as February that biotech CEOs were talking enthusiastically to Fierce about a positive “shift in the ...
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...
The FDA’s recently unveiled plausible mechanism framework may have been forged with i | The FDA’s newly launched plausible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results